Description
Global Nausea Medicine Market Research Report—Forecast till 2027
Market Synopsis
The global Nausea Medicine Market is anticipated to witness a notable CAGR of 7.83% to surpass USD 2423.26 Million by the forecast period of 2027. Nausea medicines are used to treat conditions such as nausea and vomiting. The global market growth is attributed to the rising cases of cancer increase in gastrointestinal diseases, and growing geriatric population, sedentary lifestyle, and unhealthy diet.
The global Nausea Medicine Market is expected to register a healthy market growth during the review period owing to the increasing cases of cancer worldwide. The United States has more patients of cancer patients as per the study of the national cancer Institute approximately 1.8 Million people will be diagnosed with cancer in 2020. In 2017, as per the Cancer Research UK, in females in the UK, there were more than 179,000 new cancer cases and in males in the UK, there were around 187,000 new cancer cases that are likely to propel the market in the future. However, a high preference for home remedies is anticipated to restrain the growth of this market during the review period. Furthermore, collaborations between large drug manufacturing companies and small companies are expected to register the lucrative opportunity for the growth of the global Nausea market during the assessment period.
Market Segmentation
Global Nausea Medicine Market has been classified into Type, Mode of Administration, Indication, and Distribution Channel.
Based on the type, the nausea medicine market has been divided into antagonists, cannabinoids, antihistamines, and others. The nausea medicine market, in terms of the mode of administration category, is classified into oral, intravenous, and others. The nausea medicine market, based on indication, is classified into oncology, gastroesophageal reflux disease (GERD), motion sickness, and others. Based on distribution channels the market has been classified into hospital/retail pharmacies and online.
Based on indication, the oncology segment held the largest share of 39.84% in 2019 because of the rising number of patients experiencing nausea associated with chemotherapeutic drug use.
Regional Analysis
Geographically, Global Nausea Medicine Market has been classified into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to lead the global nausea medicine market during the review period owing to the presence of major manufacturers, increasing awareness about early disease diagnosis, and the increasing prevalence of gastrointestinal diseases.
The European market is expected to register as the second-largest market for nausea medicine. The regional market is attributed to the biopharmaceutical sector, improving economies, high disposable income per individual, and increased healthcare spending market in this region.
The market in Asia-Pacific is anticipated to exhibit substantial market growth during the review period because of growing awareness about diseases, government support to improve the healthcare sector, and increasing geriatric population.
Key Players
The Major Players in the Global Nausea Medicine Market are Novartis AG (Switzerland), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline PLC (UK), Pfizer Inc. (US), Sanofi S.A. (France), Mylan NV (US), AstraZeneca (UK), Cipla Inc. (India), and others.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Table of Contents
TABLE OF CONTENT
1 EXECUTIVE SUMMARY
1.1 OVERVIEW 14
1.1.1 MARKET SYPNOSIS 14
2 MARKET INTRODUCTION
2.1 DEFINITION 15
2.2 SCOPE OF THE STUDY 15
2.3 RESEARCH OBJECTIVE 15
2.4 MARKET STRUCTURE 15
2.5 ASSUMPTIONS & LIMITATIONS 16
3 RESEARCH METHODOLOGY
3.1 DATA MINING 17
3.2 SECONDARY RESEARCH 18
3.3 PRIMARY RESEARCH 18
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19
3.5 FORECASTING TECHNIQUES 20
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21
3.6.1 BOTTOM-UP APPROACH 22
3.6.2 TOP-DOWN APPROACH 22
3.7 DATA TRIANGULATION 23
3.8 VALIDATION 23
4 MARKET DYNAMICS
4.1 OVERVIEW 24
4.2 DRIVERS 25
4.2.1 GROWING CASES OF CANCER 25
4.2.2 RISE IN GASTROINTESTINAL DISEASES 25
4.2.3 INCREASING GERIATRIC POPULATION, SEDENTARY LIFESTYLE, AND UNHEALTHY DIET 25
4.3 RESTRAINTS 26
4.3.1 HIGH PREFERENCE FOR HOME REMEDIES 26
4.4 OPPORTUNITIES 27
4.4.1 COLLABORATIONS BETWEEN LARGE DRUG MANUFACTURING COMPANY AND SMALL COMPANIES 27
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 28
5.1.1 R&D AND DESIGNING 29
5.1.2 MANUFACTURING 29
5.1.3 DISTRIBUTION & SALES 29
5.1.4 POST-SALES SERVICES 29
5.2 PORTER’S FIVE FORCES MODEL 30
5.2.1 BARGAINING POWER OF SUPPLIERS 31
5.2.2 BARGAINING POWER OF BUYERS 31
5.2.3 THREAT OF NEW ENTRANTS 31
5.2.4 THREAT OF SUBSTITUTES 31
5.2.5 INTENSITY OF RIVALRY 31
6 GLOBAL NAUSEA MEDICINE MARKET, BY TYPE
6.1 OVERVIEW 32
6.2 ANTAGONISTS 33
6.3 ANTIHISTAMINES 33
6.4 CANNABINOIDS 34
6.5 OTHERS 34
7 GLOBAL NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION
7.1 OVERVIEW 35
7.2 INTRAVENOUS 36
7.3 ORAL 36
7.4 TRANSDERMAL 37
8 GLOBAL NAUSEA MEDICINE MARKET, BY INDICATION
8.1 OVERVIEW 38
8.2 ONCOLOGY 39
8.3 GASTROESOPHAGEAL REFLUX DISEASE (GERD) 39
8.4 MOTION SICKNESS AND SEASICKNESS 40
8.5 OTHERS 40
9 GLOBAL NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW 41
9.2 HOSPITALS PHARMACY/ RETAIL PHARMACY 42
9.3 ONLINE 42
10 GLOBAL NAUSEA MEDICINE MARKET, BY REGION
10.1 OVERVIEW 43
10.2 AMERICAS 44
10.2.1 NORTH AMERICA 46
10.2.1.1 US 48
10.2.1.2 CANADA 49
10.2.2 SOUTH AMERICA 51
10.3 EUROPE 53
10.3.1 WESTERN EUROPE 55
10.3.1.1 GERMANY 57
10.3.1.2 FRANCE 58
10.3.1.3 UK 60
10.3.1.4 ITALY 61
10.3.1.5 SPAIN 62
10.3.1.6 REST OF WESTERN EUROPE 64
10.3.2 EASTERN EUROPE 65
10.4 ASIA-PACIFIC 67
10.4.1 CHINA 69
10.4.2 JAPAN 70
10.4.3 INDIA 72
10.4.4 AUSTRALIA 73
10.4.5 SOUTH KOREA 74
10.4.6 REST OF ASIA-PACIFIC 76
10.5 MIDDLE EAST & AFRICA 78
10.5.1 MIDDLE EAST 80
10.5.2 AFRICA 81
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW 83
11.2 MAJOR PLAYERS IN THE GLOBAL NAUSEA MEDICINE MARKET 83
11.3 COMPETITIVE BENCHMARKING 84
11.4 COMPETITOR DASHBOARD 85
11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES 85
11.5.1 ACQUISITIONS 85
12 COMPANY PROFILES
12.1 SANOFI S.A. 86
12.1.1 COMPANY OVERVIEW 86
12.1.2 FINANCIAL OVERVIEW 86
12.1.3 PRODUCTS/SERVICES OFFERED 87
12.1.4 KEY DEVELOPMENTS 87
12.1.5 SWOT ANALYSIS 87
12.1.6 KEY STRATEGIES 87
12.2 NOVARTIS AG 88
12.2.1 COMPANY OVERVIEW 88
12.2.2 FINANCIAL OVERVIEW 88
12.2.3 PRODUCTS/SERVICES OFFERED 89
12.2.4 KEY DEVELOPMENTS 89
12.2.5 SWOT ANALYSIS 89
12.2.6 KEY STRATEGIES 89
12.3 MERCK & CO., INC. 90
12.3.1 COMPANY OVERVIEW 90
12.3.2 FINANCIAL OVERVIEW 90
12.3.3 PRODUCTS/SERVICES OFFERED 91
12.3.4 KEY DEVELOPMENTS 91
12.3.5 SWOT ANALYSIS 91
12.3.6 KEY STRATEGIES 91
12.4 GLAXOSMITHKLINE PLC 92
12.4.1 COMPANY OVERVIEW 92
12.4.2 FINANCIAL OVERVIEW 92
12.4.3 PRODUCTS/SERVICES OFFERED 93
12.4.4 KEY DEVELOPMENTS 93
12.4.5 SWOT ANALYSIS 93
12.4.6 KEY STRATEGIES 94
12.5 MYLAN NV 95
12.5.1 COMPANY OVERVIEW 95
12.5.2 FINANCIAL OVERVIEW 95
12.5.3 PRODUCTS/SERVICES OFFERED 96
12.5.4 KEY DEVELOPMENTS 96
12.5.5 SWOT ANALYSIS 96
12.5.6 KEY STRATEGIES 96
12.6 PFIZER INC. 97
12.6.1 COMPANY OVERVIEW 97
12.6.2 FINANCIAL OVERVIEW 97
12.6.3 PRODUCTS/SERVICES OFFERED 98
12.6.4 KEY DEVELOPMENTS 98
12.6.5 SWOT ANALYSIS 98
12.6.6 KEY STRATEGIES 98
12.7 F. HOFFMANN-LA ROCHE LTD 99
12.7.1 COMPANY OVERVIEW 99
12.7.2 FINANCIAL OVERVIEW 99
12.7.3 PRODUCTS/SERVICES OFFERED 100
12.7.4 KEY DEVELOPMENTS 100
12.7.5 SWOT ANALYSIS 100
12.7.6 KEY STRATEGIES 100
12.8 ASTRAZENECA 101
12.8.1 COMPANY OVERVIEW 101
12.8.2 FINANCIAL OVERVIEW 101
12.8.3 PRODUCTS/SERVICES OFFERED 102
12.8.4 KEY DEVELOPMENTS 102
12.8.5 SWOT ANALYSIS 102
12.8.6 KEY STRATEGIES 102
12.9 CIPLA INC. 103
12.9.1 COMPANY OVERVIEW 103
12.9.2 FINANCIAL OVERVIEW 103
12.9.3 PRODUCTS/SERVICES OFFERED 104
12.9.4 KEY DEVELOPMENTS 104
12.9.5 SWOT ANALYSIS 104
12.9.6 KEY STRATEGIES 104
13 APPENDIX
13.1 REFERENCES 105
13.2 RELATED REPORTS 105
Reviews
There are no reviews yet.